NASDAQ:ALBO - Albireo Pharma News Headlines

Sign in or create an account to add this stock to your watchlist.
$35.61 -0.37 (-1.03 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$35.98
Today's Range$35.00 - $36.28
52-Week Range$19.10 - $38.69
Volume25,369 shs
Average Volume74,996 shs
Market Capitalization$428.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72

Headlines

Albireo Pharma (NASDAQ ALBO) News Headlines

Source:
DateHeadline
Albireo Pharma Inc (ALBO) Expected to Post Q2 2019 Earnings of ($1.42) Per ShareAlbireo Pharma Inc (ALBO) Expected to Post Q2 2019 Earnings of ($1.42) Per Share
www.americanbankingnews.com - May 16 at 7:57 AM
Financial Survey: Takeda Pharmaceutical (TKPYY) versus Albireo Pharma (ALBO)Financial Survey: Takeda Pharmaceutical (TKPYY) versus Albireo Pharma (ALBO)
www.americanbankingnews.com - May 15 at 8:31 AM
Albireo Pharma (ALBO) Receives Outperform Rating from William BlairAlbireo Pharma (ALBO) Receives Outperform Rating from William Blair
www.americanbankingnews.com - May 14 at 7:59 AM
Albireo Pharma (ALBO) Releases Quarterly  Earnings Results, Misses Estimates By $0.02 EPSAlbireo Pharma (ALBO) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 10 at 1:41 PM
Albireo Pharma, Inc. (ALBO) Q1 2019 Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 10 at 9:38 AM
Albireo And Elobixibat In NASH, And The Market AssessmentAlbireo And Elobixibat In NASH, And The Market Assessment
seekingalpha.com - May 9 at 6:22 PM
Albireo Reports First Quarter 2019 Financial ResultsAlbireo Reports First Quarter 2019 Financial Results
www.globenewswire.com - May 9 at 9:37 AM
-$1.37 Earnings Per Share Expected for Albireo Pharma Inc (ALBO) This Quarter-$1.37 Earnings Per Share Expected for Albireo Pharma Inc (ALBO) This Quarter
www.americanbankingnews.com - May 7 at 5:50 AM
Albireo Pharma Inc (ALBO) Expected to Announce Quarterly Sales of $1.20 MillionAlbireo Pharma Inc (ALBO) Expected to Announce Quarterly Sales of $1.20 Million
www.americanbankingnews.com - May 6 at 1:02 AM
Albireo Pharma (ALBO) Set to Announce Earnings on ThursdayAlbireo Pharma (ALBO) Set to Announce Earnings on Thursday
www.americanbankingnews.com - May 3 at 9:58 AM
Albireo Pharma Inc (ALBO) Receives Average Recommendation of "Buy" from BrokeragesAlbireo Pharma Inc (ALBO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 3 at 4:42 AM
Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and WebcastAlbireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
www.nasdaq.com - May 2 at 9:41 AM
Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast Albireo to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast 
finance.yahoo.com - May 2 at 9:41 AM
Albireos A4250 shows positive action in mid-stage pediatric cholestasis studyAlbireo's A4250 shows positive action in mid-stage pediatric cholestasis study
seekingalpha.com - April 15 at 6:10 PM
Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019
finance.yahoo.com - April 13 at 11:24 AM
FDA clears Albireos IND for mid-stage trial of elobixibatFDA clears Albireo's IND for mid-stage trial of elobixibat
seekingalpha.com - April 11 at 10:54 AM
Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASHAlbireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
finance.yahoo.com - April 11 at 10:54 AM
Albireo to Present at Investor Conferences in AprilAlbireo to Present at Investor Conferences in April
finance.yahoo.com - April 1 at 10:11 AM
Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019Albireo to Present Clinical Data on A4250 in Alagille Syndrome and Biliary Atresia at The International Liver Congress™ 2019
finance.yahoo.com - March 27 at 10:01 AM
Albireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial OfficerAlbireo Expands Executive Leadership Team with Appointment of Pamela Stephenson as Chief Commercial Officer
finance.yahoo.com - March 21 at 6:14 PM
Avillion Appoints Dr David Chiswell OBE as Board MemberAvillion Appoints Dr David Chiswell OBE as Board Member
finance.yahoo.com - March 14 at 10:00 AM
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2018 Results - Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 7 at 5:44 PM
Albireo Pharma, Inc. (ALBO) Q4 2018 Earnings Conference Call TranscriptAlbireo Pharma, Inc. (ALBO) Q4 2018 Earnings Conference Call Transcript
finance.yahoo.com - March 7 at 5:44 PM
Albireo Reports Year-End 2018 Financial Results and Provides Pipeline UpdateAlbireo Reports Year-End 2018 Financial Results and Provides Pipeline Update
finance.yahoo.com - March 7 at 10:13 AM
Albireo to Present at Cowen and Company 39th Annual Health Care Conference - GlobeNewswireAlbireo to Present at Cowen and Company 39th Annual Health Care Conference - GlobeNewswire
globenewswire.com - March 5 at 5:47 PM
Albireo to Present at Cowen and Company 39th Annual Health Care ConferenceAlbireo to Present at Cowen and Company 39th Annual Health Care Conference
finance.yahoo.com - March 4 at 10:28 AM
Albireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC) - GlobeNewswireAlbireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC) - GlobeNewswire
globenewswire.com - March 2 at 9:11 AM
Albireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC)Albireo Recognizes Rare Disease Day and Highlights Urgent Need to Support Families Affected by Progressive Familial Intrahepatic Cholestasis (PFIC)
finance.yahoo.com - February 28 at 9:40 AM
Albireo to Report Year-End 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019Albireo to Report Year-End 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
finance.yahoo.com - February 27 at 9:44 AM
Pruritus - Pipeline Insights, 2019 - ResearchAndMarkets.com - Business WirePruritus - Pipeline Insights, 2019 - ResearchAndMarkets.com - Business Wire
www.businesswire.com - February 26 at 5:40 PM
Albireo Pharma: Small Pharma With Deep Expertise In Liver DiseasesAlbireo Pharma: Small Pharma With Deep Expertise In Liver Diseases
seekingalpha.com - February 18 at 9:56 AM
How Financially Strong Is Albireo Pharma, Inc. (NASDAQ:ALBO)?How Financially Strong Is Albireo Pharma, Inc. (NASDAQ:ALBO)?
finance.yahoo.com - February 7 at 5:30 PM
Albireos lead candidate an Orphan Drug in U.S. for rare liver disorderAlbireo's lead candidate an Orphan Drug in U.S. for rare liver disorder
seekingalpha.com - January 22 at 5:23 PM
Albireo Granted Orphan Drug Designation by FDA For Lead Product Candidate A4250 for Treatment of Biliary AtresiaAlbireo Granted Orphan Drug Designation by FDA For Lead Product Candidate A4250 for Treatment of Biliary Atresia
finance.yahoo.com - January 22 at 9:36 AM
Is Albireo Pharma, Inc. (ALBO) A Good Stock To Buy?Is Albireo Pharma, Inc. (ALBO) A Good Stock To Buy?
finance.yahoo.com - December 23 at 9:05 AM
Albireo granted Orphan Designation by EC for A4250 for treatment of biliary atresiaAlbireo granted Orphan Designation by EC for A4250 for treatment of biliary atresia
seekingalpha.com - December 18 at 9:32 AM
Albireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary AtresiaAlbireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary Atresia
finance.yahoo.com - December 18 at 9:32 AM
Albireo Pharma net loss widens in Q3Albireo Pharma net loss widens in Q3
seekingalpha.com - November 13 at 4:29 PM
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2018 Results - Earnings Call TranscriptAlbireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 13 at 4:29 PM
Albireo Reports Third Quarter 2018 Financial ResultsAlbireo Reports Third Quarter 2018 Financial Results
finance.yahoo.com - November 13 at 9:06 AM
Albireo to Present at Investor Conferences in NovemberAlbireo to Present at Investor Conferences in November
finance.yahoo.com - November 8 at 9:28 AM
Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018
globenewswire.com - November 7 at 9:36 AM
Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018
finance.yahoo.com - November 6 at 9:27 AM
Report: Exploring Fundamental Drivers Behind Manulife Financial, Baozun, AstraZeneca, Insight Enterprises, Albireo ...Report: Exploring Fundamental Drivers Behind Manulife Financial, Baozun, AstraZeneca, Insight Enterprises, Albireo ...
globenewswire.com - October 26 at 9:41 AM
Albireos A4250 Fast Trackd for rare liver diseaseAlbireo's A4250 Fast Track'd for rare liver disease
seekingalpha.com - October 17 at 4:14 PM
Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille SyndromeAlbireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome
globenewswire.com - October 17 at 9:23 AM
Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille SyndromeAlbireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome
finance.yahoo.com - October 17 at 9:23 AM
Albireo Receives FDA Fast Track Designation for A4250Albireo Receives FDA Fast Track Designation for A4250
finance.yahoo.com - October 17 at 9:23 AM
Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver MeetingsAlbireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings
finance.yahoo.com - October 15 at 9:12 AM
Albireo appoints Simon Harford as CFOAlbireo appoints Simon Harford as CFO
seekingalpha.com - October 10 at 9:16 AM
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: Blockchain

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel